FZD6 (frizzled class receptor 6) is a transmembrane Wnt receptor that mediates both canonical and non-canonical Wnt signaling pathways. In the canonical pathway, FZD6 activation leads to disheveled protein activation, GSK-3 kinase inhibition, and β-catenin nuclear accumulation 1. The non-canonical pathway involves planar cell polarity (PCP) signaling, which is critical for neural tube closure and inner ear stereocilia orientation 2. FZD6 dysfunction contributes to multiple developmental disorders: rare variants associate with neural tube defects at a 5.1-fold higher burden in patients 3, and regulatory variants in FZD6 contribute to nonsyndromic cleft lip and palate by perturbing Wnt signaling during craniofacial development 4. Beyond development, FZD6 dysregulation drives cancer pathogenesis. FZD6 is highly expressed and frequently amplified in advanced prostate cancer, where its inhibition suppresses tumor growth and sensitizes cells to genotoxic agents by impairing DNA double-strand break repair 5. In glioblastoma, FZD6 overexpression correlates with malignancy and poor prognosis, and miR-935 suppresses glioma development by directly targeting FZD6 6. Recent evidence identifies FZD6 as a causal gene in biliary atresia, where its upregulation correlates with immune dysregulation and bile duct injury, suggesting therapeutic potential 7.